Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
MWN-AI** Summary
Artiva Biotherapeutics, a clinical-stage biotechnology firm focused on developing cell therapies for autoimmune diseases and cancers, has announced the appointment of Thad Huston as its new Chief Financial Officer (CFO). Huston, who brings over 30 years of experience in finance, commercial strategy, and operations within the pharmaceutical and biotechnology sectors, is expected to play a key role as Artiva advances its lead program, AlloNK, which aims to improve treatment outcomes for patients, particularly those suffering from rheumatoid arthritis.
Fred Aslan, Artiva's CEO, expressed enthusiasm about Huston's addition to the leadership team, highlighting his relevant experience in late-stage development and global commercialization. Huston previously held significant positions at companies such as Galapagos and Kite Pharma, where he was integral to strategic transitions and operational efficiency, enhancing corporate growth and profitability.
Upon joining Artiva, Huston received an inducement grant of 220,000 restricted stock units as part of his compensation, which will vest over a four-year period. This grant aligns with Nasdaq's regulations and emphasizes the company's commitment to building a robust financial foundation as it targets upcoming clinical and regulatory milestones.
Artiva’s lead therapy, AlloNK, is designed to provide deep B-cell depletion and is currently involved in multiple clinical trials aimed at treating autoimmune diseases. The company, founded in 2019, benefits from exclusive rights to advanced NK cell manufacturing technology through its partnership with GC Cell and is headquartered in San Diego, California. As Artiva prepares to receive FDA feedback on pivotal trials, Huston's expertise is poised to guide the company towards sustained growth and value creation in the competitive biotechnology landscape.
MWN-AI** Analysis
Artiva Biotherapeutics (NASDAQ: ARTV) has made a strategic move by appointing Thad Huston as Chief Financial Officer, a decision that could significantly influence its market trajectory. Huston’s impressive background in capital allocation and operational execution, particularly within clinical stage biotechnology, positions him as a pivotal asset as Artiva pushes forward with its lead program, AlloNK, targeting autoimmune diseases.
Investors should pay close attention to the potential clinical data emerging in the first half of 2026, especially concerning AlloNK's application in rheumatoid arthritis. The feedback from the FDA on a possible pivotal trial will serve as a critical juncture, impacting not only Artiva’s immediate share price but also its longer-term valuation as clinical efficacy results are anticipated.
Moreover, the company’s strategy reflects a substantive commitment to developing effective cell therapies, focusing on affordability and accessibility, which is crucial in today's healthcare landscape. The inducement grant of 220,000 restricted stock units to Huston signals the company’s dedication to aligning executive interests with shareholder value, enhancing his commitment to driving Artiva’s growth.
Artiva operates in a highly competitive realm of cell therapies, presenting both opportunities and risks. Although the clinical trials ahead may yield transformative treatment options for patients suffering from difficult-to-treat diseases, the stock's performance will also hinge on market reactions to trial results and regulatory feedback.
In summary, Artiva Biotherapeutics presents an intriguing investment opportunity, contingent on the successful navigation of key clinical and regulatory milestones. Investors should strategically weigh their options and consider entering positions ahead of upcoming announcements, while remaining vigilant of the associated risks in this volatile biopharmaceutical environment.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation.
“We are delighted to welcome Thad to Artiva as he brings strong late-stage development and commercial expertise to our leadership team,” said Fred Aslan, M.D., president and chief executive officer of Artiva Biotherapeutics. “AlloNK has the potential to deliver deep B-cell depletion with biologics-like convenience. This is an important time for Artiva as we prepare to receive feedback from the FDA on a potential pivotal trial and share clinical efficacy data in rheumatoid arthritis in the first half of this year. Thad brings a valuable combination of financial discipline, operational rigor and commercial insight as we approach key clinical and regulatory milestones.”
“I’ve seen firsthand both the clinical impact and complexity of traditional cell therapies,” said Mr. Huston. “What excites me about AlloNK is its potential to deliver deep B-cell depletion in a consistent, scalable, outpatient-ready format with improved cost efficiency and broader reach. I look forward to partnering with the team as we advance AlloNK in rheumatoid arthritis and other autoimmune diseases and position Artiva for sustained growth.”
Mr. Huston has more than 30 years of global leadership experience spanning finance, commercial strategy, business development and operations across public companies in pharmaceuticals, biotechnology and medical devices. Most recently, he served as chief financial officer and chief operating officer at Galapagos, where he led finance, commercial, operations, quality, IT and business development through the company’s strategic transition to an oncology-focused cell therapy organization. Previously, he led finance and IT at Kite Pharma, where he drove strategic planning and operational initiatives to support growth and profitability. He has also held senior leadership roles at LivaNova and Johnson & Johnson, including group chief financial officer responsibilities in medical devices and finance leadership roles across international markets. Mr. Huston holds a B.S. in finance from Pennsylvania State University and is a certified management accountant.
Inducement Grant
In connection with the appointment of Mr. Huston as Artiva's Chief Financial Officer, Artiva’s Board of Directors approved a new employment inducement grant to Mr. Huston of 220,000 restricted stock units (the “Inducement Grant”).
The restricted stock units approved under the Inducement Grant will be granted pursuant to Artiva’s 2025 Inducement Plan (the “Inducement Plan”), with the grant effective immediately following, and contingent on, the filing of a registration statement on Form S-8 to register the shares issuable under the Inducement Plan. The restricted stock units will vest over four years, with 25% of the underlying shares vesting on February 15, 2027, and 1/12th of the remaining shares vesting quarterly thereafter, subject to Mr. Huston’s continued employment on each such date. The restricted stock units are subject to the terms and conditions of the Inducement Plan and the terms and conditions of the restricted stock unit notice and agreement covering the grant.
Artiva will grant the restricted stock units as an inducement material to Mr. Huston’s employment with Artiva in accordance with Nasdaq listing Rule 5635(c)(4).
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren’s disease and an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the appointment of Thad Huston as Chief Financial Officer of Artiva Biotherapeutics, Inc. (the “Company”) and the Company’s mission, product candidates (including their potential continued development, future commercialization, and transformative treatment of rheumatoid arthritis and other autoimmune conditions), positioning for sustained growth, clinical trials, pipeline, and strategic partnerships. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Investors
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com
Media
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
Source: Artiva Biotherapeutics, Inc.
FAQ**
How will the appointment of Thad Huston as Chief Financial Officer impact Artiva Biotherapeutics Inc. (ARTV) in terms of capital allocation and operational execution as they advance AlloNK for autoimmune diseases?
What specific feedback does Artiva Biotherapeutics Inc. (ARTV) expect from the FDA regarding their potential pivotal trial for AlloNK, and how could this influence their strategic direction?
Given Thad Huston's extensive experience, what key initiatives does Artiva Biotherapeutics Inc. (ARTV) plan to implement to enhance its late-stage development and commercial strategy for AlloNK?
How does Artiva Biotherapeutics Inc. (ARTV) plan to position itself in the competitive landscape of cell therapies, especially with AlloNK's focus on deep B-cell depletion in autoimmune diseases?
**MWN-AI FAQ is based on asking OpenAI questions about Artiva Biotherapeutics Inc. (NASDAQ: ARTV).
NASDAQ: ARTV
ARTV Trading
-1.87% G/L:
$5.3874 Last:
67,525 Volume:
$5.54 Open:
